Sirukumab (INN, USAN) (developmental code name CNTO-136, tentative brand name Plivensia) is a human monoclonal antibody designed for the treatment of rheumatoid arthritis.

[3] In December 2015 three phase III trials (SIRROUND-D, -H and -T) were collecting data.

[5] By Feb 2017 SIRROUND-D was considered to have met both co-primary endpoints.

[6] The drug was previously under development for the treatment of depression.

You can help Wikipedia by expanding it.This antineoplastic or immunomodulatory drug article is a stub.